The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded ...

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

The Centers for Medicare and Medicaid Services said late Friday that it would not cover medications such as Wegovy that are ...

Pfizer is stopping development of its experimental oral GLP-1 drug for obesity, the company announced Monday, after a patient ...

A group of Democratic senators are calling on Health and Human Services Secretary Robert F. Kennedy Jr. to keep a proposed ...

President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the ...

Health and Human Services Secretary Robert F. Kennedy Jr. has been critical of the drugs, instead placing a focus on ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Trump officials reject Medicare coverage ...

A decision by CMS to not move forward with a proposed rule allowing obesity medications to be covered under Medicare Part D ...

Tirzepatide (Mounjaro) launched in India in March 2025, promising new hope for diabetes and obesity treatment. An expert ...

Physicians are turning to other options, including older, cheaper medications, as compounding GLP-1s comes to an end.

The Trump administration announced Friday that it is not moving forward with a Biden-era proposal that would have expanded ...